Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
Dimitrios C. Mastellos, Bruno G. P. Pires da Silva, Benedito Antônio Lopes da Fonseca, Natasha Peixoto Fonseca, Maria Auxiliadora‐Martins, Sara Mastaglio, Annalisa Ruggeri, Marina Sironi, Peter Radermacher, Akrivi Chrysanthopoulou, Panagiotis Skendros, Konstantinos Ritis, Ilenia Manfra, Simona Iacobelli, Markus Huber‐Lang, Bo Nilsson, Despina Yancopoulou, E. Sander Connolly, Cecília Garlanda, Fabio Ciceri, Antonio M. Risitano, Rodrigo T. Calado, John D. Lambris
Topics & Concepts
EculizumabImmunologyComplement systemComplement component 5ARDSMedicineInflammationThrombotic microangiopathyBlockadeNeutrophil extracellular trapsAntibodyLungInternal medicineReceptorDiseaseCOVID-19 Clinical Research StudiesComplement system in diseasesSARS-CoV-2 and COVID-19 Research